Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Debt to Equity (2021 - 2026)

bioAffinity Technologies has reported Debt to Equity over the past 6 years, most recently at $0.01 for Q1 2026.

  • Quarterly Debt to Equity fell 68.23% to $0.01 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $0.01 through Mar 2026, down 68.23% year-over-year, with the annual reading at $0.01 for FY2025, 26.8% down from the prior year.
  • Debt to Equity was $0.01 for Q1 2026 at bioAffinity Technologies, up from $0.01 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.04 in Q3 2022 and troughed at -$0.02 in Q2 2025.
  • The 5-year median for Debt to Equity is $0.01 (2024), against an average of $0.01.
  • The largest YoY upside for Debt to Equity was 663.46% in 2025 against a maximum downside of 424.4% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.02 in 2022, then crashed by 77.07% to $0.01 in 2023, then soared by 48.36% to $0.01 in 2024, then decreased by 26.8% to $0.01 in 2025, then skyrocketed by 87.23% to $0.01 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Debt to Equity are $0.01 (Q1 2026), $0.01 (Q4 2025), and $0.0 (Q3 2025).